ClinConnect ClinConnect Logo
Search / Trial NCT02229994

Development of a New Tool for Dyspnea Measurement in Chronic Respiratory Diseases

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Aug 29, 2014

Trial Information

Current as of May 21, 2025

Completed

Keywords

Dyspnea Self Administered Questionnaire Chronic Respiratory Disease Copd Diffuse Interstitial Lung Diseases Pulmonary Arterial Hypertension Cystic Fibrosis

ClinConnect Summary

Dyspnea is a cardinal Respiratory symptom.

According to the ATS dyspnea is the term used to characterize a subjective experience of breathing discomfort, covering qualitatively distinct sensations of varying intensity.

The subjective nature of dyspnea and the high complexity of its determinants explain the often moderate correlations obtained with physiological data. Dyspnea must therefore be measured specifically.

The aim of this study is the cross-sectional and longitudinal psychometric validation of a self-administered dyspnea questionnaire (assessing the impact of dyspnea on activiti...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1) Sample1: COPD GOLD / ATS \> 2 without major co-morbidity
  • Sample 1A: n = 50: group of patients with no change in usual care and no acute event (evaluation of reproducibility)
  • Sample1B: n = 60: patients assessed before and after a qualifying period of pulmonary rehabilitation
  • 2) Sample 2 (n = 30): diffuse interstitial lung diseases Criteria: Pulmonary Fibrosis: Idiopathic or nonspecific interstitial lung diseases (NILD) according to international criteria (ATS), sarcoidosis with parenchymal lesions (old classification stage II and III), and exceptionally alveolar proteinosis.
  • 3) Sample 3 (n = 30) primary or secondary arterial pulmonary hypertension (post embolic .....).
  • 4) Sample4 (n = 30): Adult with Cystic fibrosis.
  • 5) patient with stable Status (no exacerbation for at least one month)
  • Exclusion Criteria:
  • 1) Patient under 18 years
  • 2) Inability to fill in questionnaires
  • 3) Other respiratory disease
  • 4) left symptomatic heart failure
  • 5) Obesity with a BMI\> 35 kg/m2
  • 6) Inability to perform PFT (Pulmonary Function Testing)
  • 7) Pregnant or breastfeeding woman
  • 8) Patient unable to consent
  • 9) Lack of social insurance coverage
  • 10) Patient in exclusion period because of another protocol

About Assistance Publique Hôpitaux De Paris

Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.

Locations

Paris, , France

Patients applied

0 patients applied

Trial Officials

Thierry Perez, MD

Study Chair

CHRU de Lille / Hôpital Calmette - France

Nicolas ROCHE, MD, PhD

Principal Investigator

APHP- Hopital Cochin

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials